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Abstract Mast cells have traditionally been considered as
eVector cells in allergy but during the last decade it has
been realized that mast cells are essentially involved in the
mechanisms of innate and acquired immunity. Upon activa-
tion by anaphylactic, piecemeal degranulation or degranu-
lation-independent mechanisms mast cells can secrete
rapidly or slowly a number of soluble mediators, such as
serine proteinases, histamine, lipid-derived mediators, cyto-
kines, chemokines and growth factors. Mast cells can
express cell surface co-stimulatory receptors and ligands,
and they can express MHC class II molecules and thereby
present antigens. These soluble factors and cell surface
molecules can interact with other cells, such as endothelial
cells, keratinocytes, sensory nerves, neutrophils, T cell sub-
sets and antigen presenting cells which are essential eVec-
tors in the development of skin inXammation. Besides
promoting inXammation, mast cells may attempt in some
circumstances to suppress the inXammation and epidermal
growth but the regulation between suppressive and proin-
Xammatory mechanisms is unclear. Psoriasis is character-
ized by epidermal hyperplasia and chronic inXammation
where tryptase- and chymase-positive MCTC mast cells are
activated early in the developing lesion and later the cells
increase in number in the upper dermis with concomitant
expression of cytokines and TNF superfamily ligands as
well as increased contacts with neuropeptide-containing
sensory nerves. Due to the intimate involvement of mast
cells in immunity and chronic inXammation the role of mast
cells in psoriasis is discussed in this review.
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Introduction
Mast cells are long-lived cells that are strategically located
at sites, such as the upper dermal skin, respiratory tract and
bowel mucosa, where the host tissue is exposed to external
antigens and microbes. Human mast cells can be divided
into MCTC and MCT subtypes based on their proteinase
composition: MCTC cells contain tryptase, chymase, car-
boxypeptidase and a cathepsin G-like proteinase whereas
MCT cells contain only tryptase [78, 162, 202]. MCC mast
cell type with only chymase and carboxypeptidase has also
been identiWed in human tissues [202] though there are
results from skin organ cultures suggesting that it may rep-
resent an apoptotic mast cell from which tryptase has dis-
solved away [96]. MCTC mast cell is the predominant cell
type in the skin and bowel submucosa, whereas MCT cells
predominate in the lung and bowel mucosa [78, 202].
Traditionally, mast cells are known to be activated to
release mediators by allergen cross-linking IgE molecules
and their high aYnity FcRI receptors on the cell membrane.
However, the activation mechanisms are far more complex
and versatile. In addition to IgE-dependent mechanism,
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dent mechanism since they constitutively express the
FCRIIa receptor [217]. Furthermore, the high-aYnity IgG
receptor, FcRI/CD64, can be induced in in vitro cultured
mast cells by interferon- [137]. Interestingly, mast cells in
the psoriatic lesion, where also interferon- is expressed,
show expression of CD64 [187]. Recently, mast cells have
been reported to express a range of toll-like receptors which
can be activated by microbial products [29]. Mast cells can
also be activated for mediator release by numerous endoge-
nous peptides and proteins, including complement products
C3a and C5a [38], neuropeptides, such as substance P (SP)
and vasoactive intestinal peptide (VIP) [23], stem cell fac-
tor (SCF) [35], tumor necrosis factor (TNF) [192], tryptase
[122], and -melanocyte-stimulating hormone [56]. Corti-
cotropin-releasing hormone has been found to induce selec-
tive release of vascular endothelial growth factor (VEGF)
from human mast cells [17], a factor which is essentially
involved in angiogenesis and capillary growth. Human
mast cell activation by means of reverse signalling through
CD30 ligand is a novel pathway for mast cell activation and
chemokine secretion [42]. It should be realized that the
activation of mast cells for mediator release is not simply
an on–oV mechanism, i.e., no activation or rapid and exten-
sive anaphylactic degranulation. Mast cells can undergo
also slow peacemeal degranulation [34], exosome secretion
[172], and selective degranulation-independent mediator
secretion [17, 42].
The physiological role of mast cells in the skin is not
well known. It appears that mast cells are essential eVector
cells in protecting the skin from, e.g., severe bacterial and
parasite infections [113, 171] and from severe venom reac-
tions after snake bites and insect stings [117]. However,
there is growing evidence suggesting that mast cells are
also essentially involved in inXammatory pathomechanisms
of chronic diseases. This is understandable since mast cells
can produce, store and release upon activation numerous
mediators that can potentially aVect the immune system and
promote inXammation. These can be categorised into pre-
formed mediators and newly-synthesized mediators. Pre-
formed mediators stored in the secretory granules include,
e.g., tryptase, chymase, carboxypeptidase, a cathepsin G-
like proteinase, histamine, heparin proteoglycan, chondroi-
tin sulphate E, acidic hydrolases, and various cytokines and
growth factors. Newly synthesized mediators include pros-
taglandin D2, leukotriene C4 and varying amounts of other
lipid-derived mediators. In addition, mast cells can be
induced to de novo synthesis of a range of cytokines, che-
mokines, growth factors, and cell membrane molecules,
such as chemokine receptors, receptor ligands, toll-like
receptors, MHC class II molecules and co-stimulatory mol-
ecules, all of which are crucial in inducing an immune and
inXammatory reaction [29, 46, 83, 160].
Psoriasis is characterized by chronic inXammation and
epidermal hyperplasia where numerous inXammatory and
immune cells function simultaneously, and the involvement
of mast cells in this complex cellular and molecular net-
work has become obvious. During the last decade many
reports have shown that mast cells are not just bystander
cells in inXammatory diseases but rather crucial for immu-
nity as reported in a news article entitled “Mast cells show
their might” (Science 2007; 317:614–616). Therefore, in
this review the role of mast cells in the development of pso-
riatic lesion is discussed.
Mast cells in the psoriatic lesion
The presence of numerous mast cells in the psoriatic lesion,
especially in the subepidermal connective tissue, was rec-
ognized many decades ago as reviewed by Cox [27]. After
these observations, several other investigators conWrmed
that the number of mast cells is increased in the upper der-
mis of the psoriatic lesion [59, 60, 80, 189], and it is the
MCTC type of mast cells that are increased in number in the
uppermost dermis of the psoriatic lesion [61]. However,
this change is not speciWc to psoriasis since MCTC mast
cells are similarly increased in number in superWcial
spreading basal cell carcinoma [31], and mast cells in
chronic leg ulcers are predominantly of this MCTC type
[74]. Even though mast cells can only rarely be seen in the
epidermis of the healthy-looking skin, the presence of mast
cells in close association with the epidermis of the psoriatic
lesion is a typical feature and sometimes mast cells are
present even inside the lesional epidermis [59]. Intraepider-
mal mast cells, however, have also been associated with
other chronic inXammatory skin diseases with epidermal
proliferation, such as pemphigus vegetans, dermatitis vege-
tans and pseudoepitheliomatous diseases [53] as well as
chronic leg ulcers [11].
The appearance of degranulated mast cells is a typical
feature in the early developing psoriatic lesion as reported
by several investigators [13, 27, 168]. Schubert and Christ-
ophers [168] treated psoriatic plaques with a potent steroid
under occlusion for 6–10 days and then allowed a relapse to
occur. During the developing relapse, the earliest changes
were found to be endothelial swelling followed by the
appearance of degranulated mast cells around the postcapil-
lary venules, and hours later activated macrophages were
present. Brody [13] examined a series of biopsies taken
from the early phases of acute eruptive guttate psoriasis and
demonstrated diVerent types of mast cell degranulation in
the psoriatic lesion. He reported that degranulated mast
cells are an early and constant feature in the evolution of
acute guttate psoriasis. Toruniowa and Jablonska [188]
induced a Köbner reaction in the healthy-looking psoriatic123
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lesion. A signiWcant increase in mast cell numbers took
place on day 4, when compared to mast cell numbers in
control skin, and this increase peaked on day 14 simulta-
neously with the appearance of the Köbners phenomenon.
These Wndings suggest that mast cells residing in the dermis
are among the earliest cells which show activation in the
initial phases leading to mast cell degranulation and
increase in cell number. The increased interstitial histamine
concentration in the psoriatic plaque, as measured with the
microdialysis technique, also suggests elevated mast cell
activity and degranulation [97, 147].
Regulation of mast cell number and activity 
in the psoriatic skin
The mechanisms for the increase in mast cell numbers in
chronic inXammation, such as in psoriasis, is not clear.
The stem cell factor (SCF) (Kit ligand) is a well-known
and essential factor for the growth, migration, activation
and survival of human mast cells developed and cultured
in vitro [93, 123, 133, 134] or isolated from skin speci-
mens [45, 85]. SCF injected subcutaneously induces ana-
phylactic-like activation and degranulation of dermal mast
cells in situ followed by inXammatory cell recruitment
such as neutrophils, eosinophils and basophils [35]. Pro-
longed subcutaneous injection of SCF for up to 14 days
results in mast cell and melanocyte hyperplasia in the skin
[26]. Mature mast cells isolated from human skin speci-
mens can be cultured in serum-free medium in the pres-
ence of SCF, and these cells even proliferate and maintain
their proteinase phenotype in such conditions [85] sug-
gesting that a mature MCTC mast cell is capable of prolif-
eration in response to SCF during a disease process. In a
mouse model of skin inXammation, Kit expression is
essential for mast cell accumulation which further sup-
ports the importance of SCF–Kit interaction [201].
Another explanation for the increased mast cell numbers
may be that the survival of resting and activated mast cells
is enhanced due to survival gene expression or other mech-
anisms [148, 210] and/or mast cells and their hematopoi-
etic progenitors are recruited from the circulation. For
example, mast cells express at least nine chemokine recep-
tors [83] and SCF, TGF-, RANTES and stromal cell-
derived factor-1 have eYciently induced migration of
human mast cells in vitro and therefore they are potent
candidates for chemoattraction of mast cells to the tissue
site [82, 132, 139]. In addition to SCF, several other fac-
tors have been reported to modulate human mast cell
development or survival in vitro, such as IL-3 to IL-6
[213], IL-9 [112], thrombopoietin [158], nerve growth fac-
tor [89], and endothelial cells [118].
Since SCF is the crucial factor for mast cell growth,
migration and survival, the expression of SCF in inXamed
skin has previously been studied. Yamamoto et al. [212]
demonstrated that SCF immunoreactivity is localized to
keratinocytes in the acanthotic psoriatic epidermis and also
to endothelial cells and Wbroblasts. In addition, serum lev-
els of SCF were increased in psoriatic patients compared
with those in normal subjects [212]. Furthermore, the num-
ber of SCF-positive cells is markedly higher in the dermis
and epidermis of the psoriatic lesion than in those of corre-
sponding non-lesional skin [73]. The increase of SCF in
inXamed psoriatic skin is, however, not a speciWc feature of
psoriasis since SCF-positive cells are numerous also in
chronic leg ulcers and transiently increased in number in
the initial phases of normal wound healing [73]. Further-
more, SCF is increasingly upregulated in basal cell carci-
noma and also in tumor cells [211]. Interestingly, even mast
cells themselves can produce SCF [203, 215]. The receptor
for SCF, Kit, is a transmembrane tyrosine kinase receptor
that is practically exclusively expressed by mast cells in the
dermis and by melanocytes in the epidermis [67, 73]. In the
psoriatic lesion, mast cells are strongly immunopositive for
Kit when compared to mast cells in the non-lesional skin
(Table 1) [73]. However, Kit is strongly expressed in mast
cells in chronic leg ulcers and in the late phases of normal
wound healing as well [73]. Therefore, the SCF–Kit inter-
action provides one plausible explanation for the increase
in mast cell numbers and enhanced mast cell activity in
chronic skin inXammation, including psoriasis.
Several eVective drugs used in the treatment of psoriasis
can aVect the activity and/or number of mast cells. Low-
strength anthralin therapy has been found to reduce the
number of mast cells in the psoriatic plaque [188]. The
treatment with 0.05% clobetasol-17-propionate cream for
up to 4 weeks inhibits allergen-induced wheal reaction and
reduces markedly the number of mast cells in the skin
[151]. Corticosteroids may possibly inhibit the production
of SCF in dermal cells leading to reduced survival of mast
cells [41]. However, a topical clobetasol-17-propionate
treatment of psoriatic plaques for up to 3–4 weeks did not
result in a decrease in mast cell number, nor did the 3- to 4-
week treatment with bath-PUVA, and a longer treatment
period appears to be required in order to deplete mast cell
hyperplasia in the chronic psoriatic plaque [189]. This
resistance of mast cells to topical corticosteroid may be
explained by highly increased SCF production in psoriasis
[73, 212]. Retinoids, which are widely used in the treatment
of psoriasis, have been reported to inhibit the development
of human mast cells from progenitors in vitro [67, 92] but
without reducing the number of mature mast cells in the
normal human skin [67]. Also, retinoids have been found to
inhibit histamine release from concanavalin-A stimulated
human mast cells isolated from the adenoid tissue [37].123
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inhibition of mast cell activity as well as maturation of
recruited progenitor mast cells entered to the tissue site.
Cyclosporin A is also a potent immunomodulatory drug
used in the treatment of psoriasis. However, besides its
well-known inhibitory action on T cells cyclosporin A has
long been known to inhibit histamine and LTC4 or PGD2
release from isolated human lung or skin mast cells [110,
177]. Cyclosporin A can also inhibit SCF-induced hista-
mine release [173] as well as chemokine gene induction in
human mast cells [68]. Moreover, subcutaneous injections
of cyclosporin A into asebia mice, which show epidermis
hyperplasia and dermal inXammatory changes with ele-
vated mast cell numbers, have been found to decrease mast
cell numbers in the dermis [141]. Thus, a part of the thera-
peutic eVect of cyclosporin A in psoriasis may be attributed
to the inhibition of mast cell activity and the decrease in
mast cell numbers. In addition to potent immunomodula-
tors, also H1- and H2-antihistamines have been tested in
psoriatic patients [145, 147, 219]. Based on the skin micro-
dialysis technique and histamine assays mast cells in the
psoriatic lesion are hyperreactive. A prolonged high-dose
ranitidine administration for up to 6 months to psoriatic
patients appears to improve psoriatic skin disease and nor-
malize mast cell hyperreactivity towards substance P and
codeine injections, but without aVecting mast cell numbers
[147]. However, a double-blind and placebo-controlled
multicenter study could not reveal any signiWcant therapeu-
tic eVect of ranitidine on psoriasis [219]. In a double-blind
controlled study, 10 mg cetirizine administered three times
a day for 15 days signiWcantly reduced the number of tryp-
tase-positive mast cells in the lesional skin, resulted in
some improvement in the psoriatic area and severity index
(PASI) score and erythema [145], and reduced the expres-
sion of adhesion molecules ICAM-1, ICAM-3 and LFA-1
[146]. Nevertheless, an inhibitor of mast cell degranulation,
Tiacrilast, administered topically as a 3% hydrogel for 4
weeks did not produce any signiWcant improvement in the
psoriatic plaques [191].
Mast cell serine proteinases in psoriasis
The major protein in mast cell granules, tryptase, is a tryp-
sin-like serine proteinase with 4 subunits and catalytic sites
and it shows heterogeneity in respect to glycosylated side
chains and can follow sigmoidal reaction kinetics typical
for allosteric enzymes [58, 64, 144]. The gene locus of
human tryptase in the chromosome 16p13.3 is far more
complex than originally thought: there are two major
forms, - and -tryptases, which can be divided further into
1- and 2-forms and 1-, 2- and 3-forms. Furthermore,
additional forms include -, - and -tryptases [19, 20, 199,
207, 214] of which -tryptase is a functionally and structur-
ally distinct membrane-bound enzyme in mast cells that can
eYciently be inactivated by 1-proteinase inhibitor [208,
214], -tryptase is expressed in airway epithelial cells but
apparently not markedly in mast cells [207], and -tryptase
has marked amino acid similarity with - and -tryptases
but is truncated by 40 amino acids in the carboxyterminal
end and cannot hydrolyze the canonical tryptase substrate
N-p-tosyl-Gly-Pro-Lys-p-nitronilide [199]. There is, how-
ever, a report showing that -tryptase gene is a pseudogene
without transcription in human mast cells in vitro [119].
Nevertheless, inactive - and -protryptases are constitu-
tively secreted and active -tryptase is the principal enzyme
that is packed and stored in large quantities in the secretory
granules of mast cells [64, 169]. Human -tryptase is a
ring-like tetramer with four active centers facing towards
the central oval pore [144]. This feature explains the high
Table 1 The percentage of tryptase-positive mast cells immunopositive for diVerent proteins in the upper dermis of the psoriatic skin based on
the sequential double-staining technique
The sequential double-staining technique used to generate these results is illustrated in Fig. 2
Nonlesional skin Lesional skin Number 
of subjects
References
Kit 46 § 26% 88 § 12% 10 [73]
1-Proteinase inhibitor 33 § 19% 72 § 15% 20 [62]
1-Antichymotrypsin 60 § 13% 87 § 7% 20 [62]
2-Macroglobulin 6 § 4% 17 § 7% 10 [62]
C1-esterase inhibitor 11 § 6% 14 § 10% 5 [62]
Interferon- 44 § 17% 67 § 18% 21 [2]
TNF- 15 § 15% 16 § 25% 12 [1]
CD30 ligand 8 § 11% 33 § 21% 10 [42]
Tryptase-positive cells 96–130 cells/mm2 257–308 cells/mm2 (data compiled from 
references listed above)123
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proteins and peptides since a protein has to be in a proper
orientation and has to possess a suitable conformation to
reach the buried active centers. Indeed, -tryptase is resis-
tant to common endogenous protease inhibitors and, in fact,
there are no known physiologic inhibitors for tetrameric
-tryptase. Furthermore, heparin glycosaminoglycan is
needed to stabilize -tryptase as an active tetramer and
degradation of heparin or replacement of -tryptase from
heparin by another protein or molecule can be physiological
control mechanisms—in the absence of heparin tetrameric
-tryptase dissociates reversibly into inactive-destabilized
tetramer and further to inactive monomers and monomers
with limited activity [57, 64, 164]. In accordance with this
resistance to protease inhibitors, tryptase has been found to
be catalytically active detected on skin sections from inX-
amed skin and only occasional tryptase immunoreactive
cells without enzyme activity have been detected [31, 61,
86].
In contrast to tryptase, only a single -form of human
chymase gene has been found in the protease gene locus in
chromosome 14q11.1–11.2 next to cathepsin G gene.
Mature chymase is a 30-kDa monomeric and chymotryptic
serine proteinase that is processed from prochymase by
dipeptidyl peptidase I and is stored in high quantities in
mast cell secretory granules [19, 20]. Even though both
tryptase and chymase bind eYciently to heparin, chymase-
heparin proteoglycan complexes (Mr 400–560 kDa) are
larger in size than tryptase–heparin proteoglycan com-
plexes (Mr 200–250 kDa) [52]. Furthermore, the subcellular
localization of chymase diVers from that of tryptase within
the secretory granules—chymase and cathepsin G are pref-
erentially localized in more electron-dense amorphous
granule subregions whereas tryptase resides in less elec-
tron-dense crystalline subregions [205]. These diVerences
may explain the Wndings that tryptase protein diVuses away
together with histamine whereas chymase protein tends to
remain at the site of mast cells in human skin biopsies cul-
tured and activated ex vivo [95, 96]. Thus, tryptase can
diVuse through the extracellular matrix and reach more dis-
tant target sites in the skin whereas chymase functions
rather locally. However, diVerent forms of chymase have
been described in respect to the binding aYnity to heparin–
agarose column, possibly owing to diVerences in glycosyla-
tion, and therefore chymase form with low binding aYnity
may diVuse more easily after release than the high-aYnity
form [114]. Although chymase binds eYciently to heparin,
the enzyme remains active also in the absence of heparin, a
feature which diVers from that of tryptase. However, hepa-
rin can modulate the interaction of chymase with cells, pro-
tein substrates and inhibitors [74, 159, 195]. A clearly
distinct feature of chymase is that it can be inactivated by a
range of endogenous protease inhibitors, including 1-pro-
teinase inhibitor (1-PI), 1-antichymotrypsin (1-AC)
[114, 161] 2-macroglobulin [196], secretory leukocyte
proteinase inhibitor [195] and squamous cell carcinoma
antigen-2 [165]. However, chymase can also eVectively
degrade 1-PI and 1-AC and, in fact, this reaction proceeds
faster than the inhibition of chymase by these inhibitors
[161] suggesting a complex regulation between the protein-
ase and its inhibitors. Thus, the activity of chymase is con-
trolled by protease inhibitors normally present in inXamed
tissue whereas tryptase may have a prolonged action time
after being released from mast cells. In support for this,
inactivation of chymase has been shown to take place rap-
idly in the skin, e.g., in the allergic skin wheal reaction
[155], cutaneous herpes zoster lesions [86] and skin organ
cultures [95, 96], as detected enzyme- and immunohisto-
chemically.
The MCTC type of mast cell with tryptase and chymase
is the predominant mast cell type in normal skin and these
mast cells are increased in number in the upper dermis of
the psoriatic lesion. However, meanwhile tryptase retains
its activity chymase is apparently inactivated in the upper
dermis during the development of the psoriatic lesion [59–
61]. Using the sequential double-staining technique, mast
cells in the psoriatic lesion have been shown to display
increased levels of immunoreactivity towards 1-PI, 1-AC,
2-macroglobulin and even C1-esterase inhibitor (Table 1).
Further, 1-AC-positive mast cells appeared to correlate
with reduced chymase activity in the lesion [62]. It is possi-
ble that these inhibitors are derived from the extravasated
serum and taken up by mast cells as is suggested in the case
of inter--trypsin inhibitor light chain [76], or produced in
mast cells as in the case of secretory leukocyte proteinase
inhibitor [204]. Nevertheless, the increased levels of 1-AC
and 1-PI within mast cells could well explain the reduced
chymase activity. This feature, however, is not speciWc to
psoriasis, since it has been detected, for example in basal
cell carcinoma [31] as well as chronic leg ulcers [74]. The
activation of mast cells in the inXamed skin may lead to
granule extrusion and hence loosening of tightly packed
acidic granule structure. Inhibitors presumably can then
inactivate chymase exposed to physiological pH and high
inhibitor concentration (Fig. 1). It is noteworthy, however,
that the apparent inactivation of chymase is only partial and
there is residual chymase activity which may aVect the sur-
rounding microenvironment [61, 62].
Mast cells contain large amounts of preformed -tryp-
tase and -chymase and their possible function in the
inXammatory process cannot be ignored [20]. Even though
the pathophysiological signiWcance of -tryptase in vivo is
not clear, there are several experimental Wndings which
suggest an implication for the development of psoriatic
inXammation. Tryptase has been reported to induce vascu-
lar tube formation of endothelial cells in vitro suggesting a123
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human endothelial cells for increased production of MCP-1
and IL-8 [24, 25, 91], chemokines which can attract neutro-
phils and many other cells of the immune system. Further-
more, tryptase activates peripheral blood mononuclear cells
for TNF-, IL-6 and IL-1 production [109], human neu-
trophils for IL-8 secretion [197], and human T cells for IL-
6 release [101]. Activation of these cells is very likely med-
iated via activation of the proteinase-activated receptor-2
(PAR-2) by tryptase. In experimental animals, tryptase
injected into the skin of guinea pigs induced accumulation
of neutrophils and eosinophils within 6 h and later also
other cells of the immune system [65]. In addition, also
human skin mast cells express the PAR-2 receptor and can
thus be activated by tryptase and receptor agonists [122].
Furthermore, the percentage of mast cells showing PAR-2
immunoreactivity is increased in the psoriatic lesion (Carv-
alho et al., unpublished results). This suggests that tryptase
released from mast cells can induce mast cell activation in
an autocrine or paracrine fashion leading to potentiation of
mast cell-mediated inXammation in psoriasis (Fig. 1).
Besides its proinXammatory function tryptase may also
control cell recruitment to some extent since it is capable of
cleaving eotaxin and RANTES, but not GM-CSF, MCP-1,
IL-8, TGF-1 and VEGF [142]. Tryptase-positive mast
cells are increased in number close to the psoriatic epider-
mis and, therefore, the enzyme may well aVect the base-
ment membrane and basal keratinocytes. Indeed, tryptase
has been found to degrade Wbronectin in the basement
membrane zone [87]. In addition, tryptase can activate
metalloproteinases, such as MMP-3 and MMP-9 [55, 75,
102], and pro-urokinase [174], or it can act as a gelatinase
[39]. Thus, tryptase can modify the extracellular matrix and
basement membrane directly or indirectly in order to make
space for T cells and neutrophils for migrating into the epi-
dermis. Tryptase may also aVect keratinocytes directly via
activation of PAR-2 on their surface [163]. Interestingly, in
vitro activation of keratinocytes by PAR-2 agonists results
in increased keratinocyte phagocytosis [170], ICAM-1
expression [14] and IL-8 release [70]. Furthermore, tryp-
tase has been reported to stimulate bronchial epithelial cells
to release IL-8 and express ICAM-1 [16].
Like tryptase, chymase also can have immunoregulatory
activity which may be related to the psoriatic immunopatho-
genesis, though the eVect is dependent on the availability of
Fig. 1 Hypothetical model for the interaction between mast cells and
sensory nerves in psoriasis. a Neuropeptides substance P (SP) and
vasoactive intestinal peptide (VIP) released from sensory nerves can
activate mast cells for mediator synthesis and release by a receptor-
dependent or -independent mechanism. Tryptase (Try) released can di-
Vuse through the matrix, reach more distant sites, and can degrade and
inactivate VIP and calcitonin gene-related peptide (CGRP), but not SP.
Released chymase (Chy) tends to remain at the site of activated mast
cell, it can degrade both SP and VIP, but is partially inactivated by 1-
proteinase inhibitor (1-PI) and 1-antichymotrypsin (1-AC). On the
other hand, chymase can degrade these inhibitors eYciently. Hista-
mine and tryptase can activate the sensory nerve resulting in the spread
of the signal in an axon reXex-dependent mechanism. The tryptase
receptor on nerves, proteinase-activated receptor-2 (PAR-2), is in rela-
tion to the capsaicin receptor (TRPV-1) and PAR-2 activation sensi-
tizes TRPV-1 leading to enhancement in capsaicin-induced SP and
CGRP release. Tryptase can also activate PAR-2 on mast cells poten-
tiating the reaction in an autocrine or paracrine fashion. b A confocal
laser scanning image of a neuroWlament-positive sensory nerve and a
tryptase-immunopositive mast cell (see [131]). In the dermis of a ma-
ture psoriatic lesion, a bundle of nerves (green) appears in the Wrst im-
age up left. Step by step mast cell tryptase (red) becomes visible, and
the nerves are observed in close contact with the mast cell in most im-
ages where the nerves appear yellow. At those sites, the red of mast cell
tryptase coincides with the green colour of neuroWlaments. Sixteen
consecutive laser scanning images, step size 0.2 m
123
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protease inhibitors. Human chymase injected into the skin
of guinea pigs stimulates the accumulation of neutrophils
and eosinophils at the injection sites [66]. In support for
this, chymase also stimulates chemotaxis of monocytes,
and neutrophils and chemokinesis of lymphocytes in vitro
[183]. Interestingly, chymase has been reported to stimu-
late an eosinophilic cell line EoL-1 for IL-8 synthesis and
secretion in vitro [186]. Chymase can also activate the
precursors of IL-1 family, pro-IL-1 and pro-IL-18, to
their corresponding active forms IL-1 and IL-18 [120,
140]. In addition, it can generate 31-amino acid endothe-
lin-1 that acts as a potent chemoattractant for neutrophils
and monocytes [28], and therefore chymase may promote
inXammation indirectly. Another indirect mechanism
could be the cleavage of membrane-bound SCF on stro-
mal cells by chymase, which results in the release of solu-
ble and bioactive SCF. Thus, the released SCF may have
an eVect on mast cell activity and growth during inXam-
mation [103]. Furthermore, chymase has been shown to
release matrix-bound latent TGF-1 complexes in vitro
and therefore it may participate in the regulation of the
immune system and matrix accumulation [181]. Like
tryptase, also chymase may have controlling eVects on
inXammation since chymase, as well as cathepsin G, can
eYciently degrade IL-6 and IL-13, and also IL-5 and
TNF- to some extent, but not GM-CSF [216]. In addi-
tion, chymase can degrade eotaxin, but not RANTES,
MCP-1 or IL-8 [142]. Chymase is a potent enzyme and
has to be controlled by proteinase inhibitors since it can
aVect the epidermis and cleave epidermal keratinocytes
from the substratum leading to keratinocyte apoptosis
[74] (Diaconu et al., unpublished results). It can also
degrade Wbronectin [138] and activate procollagenase
[154].
Interactions between mast cells and sensory nerves 
in psoriasis
The involvement of stress in cutaneous neurogenic inXam-
mation and sensory nerve–mast cell interaction has been
suggested in several studies [6, 143]. Neuropeptides SP and
VIP can eYciently activate human skin mast cells for rapid
histamine release in situ [71] and in vitro [23]. Further-
more, in vitro stimulation of human mast cells with SP and
VIP results in the production of proinXammatory media-
tors, such as MCP-1, IL-8, RANTES, TNF-, IL-3 and
GM-CSF [48, 100]. However, it appears that the amount of
neuropeptides in normal skin is not suYcient for inducing
marked mast cell activation, a conclusion based on the Wnd-
ings that capsaicin can induce only weak, if any, histamine
release in skin ex vivo and in situ [71, 184]. Nevertheless,
the case is diVerent in chronic skin inXammation, since
increased SP-positive nerve Wbers [128] and increased tis-
sue levels of SP and VIP [36] have been measured in the
psoriatic lesion, though there are reports showing only
increased VIP levels in the lesional skin [5, 149]. Accord-
ingly, topical capsaicin cream has been reported to be eVec-
tive in the treatment of psoriatic plaques [9] and the
mechanism for this beneWcial eVect may be that prolonged
capsaicin treatment depletes neuropeptides from nerves
[178]. Further support for the role of nerves is provided by
clinical cases where nerve damage has been reported to
clear chronic psoriasis and the lesions reappeared with
recovery of cutaneous sensation [40].
In histochemical studies, morphological contacts
between neuroWlament-positive sensory nerves and tryp-
tase-positive mast cells are more frequent in the developing
and mature psoriatic lesions than in lesion-free skin, normal
skin and lichen planus skin [129, 130]. This indicates that
the morphological basis exists for nerve–mast cell interac-
tion in psoriasis as illustrated in Fig 1. Furthermore, the
contacts between SP- and CGRP-positive Wbers and tryp-
tase-positive mast cells are increased in the uppermost der-
mis of the psoriatic lesion as well, whereas the contacts
between VIP-positive Wbers and tryptase-positive mast
cells were less frequent [131]. This suggests that especially
SP- and CGRP-positive nerves interact with mast cells in
psoriasis. However, nerve–mast cell interaction and neuro-
peptides SP and CGRP have also been linked to atopic and
nummular eczema lesions [84].
The regulatory system between nerves and mast cells in
psoriasis is evidently more complex than thought. For
example, higher doses of topical capsaicin are needed to
induce inXammation on the forearm skin of psoriatic
patients than on that of healthy controls or patients with
systemic scleroderma [50]. Even though the basal hista-
mine concentration in the psoriatic lesion is elevated, as
measured with the microdialysis technique, the topical
anaesthesia with lignocaine-prilocaine cream could not
reduce histamine level but rather increased it together with
a decrease in blood Xow [98]. One possible explanation for
this may be given by the state of exhaustion in the neuro-
genic system in chronic psoriasis. In addition, several pro-
teases can degrade neuropeptides and control their eVects.
Dipeptidyl peptidase IV (CD26) is present in the psoriatic
lesion and can cleave dipeptides from the aminoterminal
end of SP [136, 200]. Neutral endopeptidase can terminate
SP-induced skin inXammation [167], and stromelysin can
cleave SP [185]. The precursor for stromelysin, prostrom-
elysin, can be activated by mast cell tryptase [55]. Further-
more, tryptase can cleave and inactivate VIP and CGRP,
but not SP and neurokinins [43, 182, 193]. Chymase is able
to degrade both SP and VIP [18, 43] (Fig. 1), and mast cell
carboxypeptidase releases carboxyterminal leucine from123
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controlling the neuropeptide-mediated inXammation, tryp-
tase may also promote neurogenic inXammation by activat-
ing the PAR-2 receptor on nerves resulting in SP and
CGRP release [175]. However, it is not known whether the
PAR-2 receptor is upregulated in nerves in psoriasis like it
is in atopic dermatitis lesions [176]. Interestingly, PAR-2
appears to be closely related to the capsaicin receptor, tran-
sient receptor potential vanilloid receptor-1 (TRPV-1).
PAR-2 activation sensitizes TRPV-1 leading to enhance-
ment in capsaicin-induced SP and CGRP release [4]. Fur-
thermore, TRPV-1 has been localized to cutaneous SP-
positive nerve Wbers and mast cells [178]. Histamine is also
a mediator that has traditionally been known to stimulate
axon reXex, neurogenic Xare and itch in the skin. In addi-
tion, CGRP has been shown to be released in the Xare area
elicited by histamine iontophoresis [166]. The eVect of his-
tamine on cutaneous nerves and Xare can be controlled by
topical anaesthetics [150] and by nedocromil sodium and
loop diuretics, frusemide and bumetadine, drugs which
appear to inhibit the Na+/K+/2Cl¡ cotransporter in the sen-
sory nerve membranes [206]. Hence, both tryptase and his-
tamine released from mast cells can act together and
stimulate surrounding nerves and neurogenic inXammation
(Fig. 1), but the regulatory mechanisms are far from com-
plete understanding in chronic skin inXammation.
In addition to neuropeptides, also neurotrophins, such as
nerve growth factor (NGF), and its high-aYnity receptor
(TrkA) have been suggested to play a role in psoriasis,
especially in pruritic psoriasis [21, 127], and NGF may be
involved in the growth of nerves in the psoriatic lesion.
Nevertheless, human mast cells have previously been
shown to express NGF and TrkA, and release NGF upon
mast cell activation [135, 209]. Therefore, NGF released
from mast cells is one possible mediator acting as an auto-
crine growth factor for mast cells and also interacting with
nerves. Whether NGF is actually expressed in mast cells in
the psoriatic lesion needs to be clariWed. The neuropeptide,
-melanocyte-stimulating hormone, evidently acts as an
anti-inXammatory mediator and a potent modulator of the
immune system [107]. Thus, -melanocyte-stimulating hor-
mone may have potential in the regulation of psoriatic
inXammation but this needs to be studied further. Interest-
ingly, -melanocyte-stimulating hormone can sensitively,
at picomolar concentrations, activate skin mast cells for his-
tamine release [56].
Mast cells in relation to cells of the immune system
in psoriasis
The modern aspects of the immunopathogenesis of psoria-
sis have been presented in recent review articles [104, 157].
Evidently, diVerent subsets of T cells, antigen presenting
cells, neutrophils and keratinocytes are all essentially
involved in the immunoregulation in psoriasis. It is, how-
ever, noteworthy that mast cells can express a range of che-
mokines, cytokines and cell surface proteins which link
them intimately to the innate and acquired immune system
[29, 46]. It has long been known that the psoriatic lesion is
characterized by a Th1 type of cell inWltrates [190]. How-
ever, after recent discovery of the novel Th17 cell type pro-
ducing IL-17 and IL-22 it was realized that both T cell
types, Th1 and Th17, are present in the psoriatic lesion, and
Th17 cells have paramount importance in the lesion devel-
opment [105, 108, 218]. Similarly to Th1 cells, also Th17
cells are induced to diVerentiate from naïve T cells. How-
ever, the induction of Th17 cells is regulated by IL-6 and
TGF-, and IL-23 is required for the development and
maintenance of the Th17 lineage. Nevertheless, numerous
other factors have an impact on Th17 cell development, too
[22, 218]. The defective function of regulatory T cells can
also have an impact on the development of psoriatic inXam-
mation since these T cells in psoriatic patients cannot
eYciently inhibit eVector T cell activity [179].
The close interaction of mast cells with T cells has been
shown in several studies and mast cells can express soluble
factors, cell surface molecules and co-stimulatory mole-
cules which can activate diVerent subsets of T cells as
reviewed by Mekori and Metcalfe [116], and Sayed and
Brown [160]. In co-cultures of mouse mast cells and T
cells, both cell-cell proximity and soluble factors, espe-
cially TNF, can contribute to T cell proliferation, and mast
cells can activate multiple T cell subsets, such as CD4+,
CD8+, Th1, Th2, Tc1, Tc2, TCR+ and CD4+CD62L¡ T
cells [124]. The same group demonstrated later that this
mast cell-induced enhancement of T cell activation is sig-
niWcantly dependent on the secretion of soluble TNF and
direct cell–cell interactions between mast cell OX40 ligand
and T cell OX40 receptor [125]. Similarly, human mast
cells have been shown to activate T cells in vitro by direct
cross-talk between OX40 ligand on mast cells and OX40
receptor on T cells [90]. Mast cells have previously been
shown to express another member of the TNF superfamily
on the cell membrane, CD30 ligand, that is functional and
can activate lymphoma cell lines in vitro [121]. Mast cells
can act as antigen-presenting cells to T cells in an MHC
class I- and MHC class II-dependent manner in vitro [46,
116, 160], and human mast cells have been shown to
express MHC class II and to present staphylococcal super-
antigens to CD4+ T cell hybridomas leading to T cell acti-
vation [152]. Furthermore, human cord blood-derived mast
cells exposed to diVerent gram-negative and gram-positive
bacteria in vitro have been shown to bind and phagocytose
several bacteria strains, such as Staphylococcus aureus,
leading to death of bacteria and TNF- secretion from mast123
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human mast cells cultured in vitro have been shown to
express CD80 and CD86 that are needed as co-stimulatory
signals for eYcient T cell activation [44, 152]. In fact,
human mast cells express a range of diVerent CD antigens
and ICAM-1, VLA-4, Mac-1 and to some extent also LFA-
1 [47, 77]. The adhesion molecules on mast cells, espe-
cially ICAM-1, can interact with T cells leading to T cell
activation, but on the other hand mast cells can also be acti-
vated upon cell–cell contact with activated T cells resulting
in enhanced mast cell degranulation, migration and adhe-
sion to extracellular matrix and endothelial cell ligands
[12]. In recent experiments with mice, mast cells and their
TNF have been reported to enhance antigen- and Th17 cell-
dependent development of a neutrophil-rich inXammatory
response in airways [126] suggesting that mast cells can
promote Th17 cell-dependent inXammation in vivo. In
addition to local actions in the skin previous Wndings in
mice show that as a result of dinitroXuorobenzene-induced
contact hypersensitivity mast cells are activated and they
migrate to draining lymph nodes wherein they can mediate
T cell recruitment [198]. Further support for mast cell-
induced lymph node activation and hypertrophy is provided
by the study showing that activation of mast cells in mouse
footpad by injection of Escherichia coli bacteria or com-
pound 48/80 results in rapid draining of mast cell-derived
preformed TNF to lymph nodes wherein it induces hyper-
trophy and recruitment of circulating T cells [115]. Further,
Jawdat et al. [81] have demonstrated that the mast cell-
dependent lymph node activation in mice can be mast cell
TNF-dependent in an allergic response or TNF-indepen-
dent in a response to bacterial peptidoglycan injection.
DiVerent types of professional antigen presenting cells,
such as Langerhans cells, macrophages, plasmacytoid den-
dritic cells and myeloid dendritic cells, have been presented
to be essentially involved in the initiation of the psoriatic
lesion and regulation of T cell responses [104, 157]. The
juxtaposition of dendritic cells and mast cells in the upper
dermis, however, suggests that these cells have to be in
close relationship between each other. Indeed, experimental
studies have shown that mast cells are capable of stimulat-
ing Langerhans cells and dendritic cells. For example, mast
cell activation in mouse ear pinna induced by an IgE-
dependent mechanism or by a bacterial peptidoglycan
injection is crucial in the stimulation of Langerhans cell
migration to draining lymph nodes [81]. Similarly, mast
cells and their TNF are needed for optimal migration of
dendritic cells to local lymph nodes after induction of con-
tact hypersensitivity in mouse ear pinna with FITC [180].
One potent mechanism for dendritic cell activation may be
via mast cell-derived exosomes. These vesicles from mouse
bone marrow-derived mast cells, located in the endocytic
pathway and capable of harboring exogenous antigens,
have been shown to stimulate and maturate mouse dendritic
cells leading to strongly enhanced antigen presenting activ-
ity to T cells [172]. In co-cultures of human in vitro-devel-
oped mast cells and monocyte-derived dendritic cells, mast
cells activated by FcRI cross-linking induced maturation
of dendritic cells which in turn polarized naïve T cells
towards the Th2 lineage, an eVect largely dependent on
secreted histamine and contacts between mast cells and
dendritic cells [94]. In fact, histamine has previously been
proved eVective in dendritic cell maturation and activation.
For example, histamine receptor H1 and H3 stimulation on
dendritic cells results in proinXammatory cytokine produc-
tion, Th1 priming and increased antigen presenting activity,
whereas H2 stimulation leads to IL-10 induction and Th2 or
tolerance priming [3]. Nevertheless, it is currently not
known how these interactions between mast cells and anti-
gen presenting cells are actually working in the psoriatic
skin or in mouse models of psoriasis. Histamine has also
been shown to stimulate human keratinocytes through H1
receptor for increased expression of IL-6, IL-8, GM-CSF,
TNF-, ICAM-1 and diVerent matrix metalloproteinases,
and histamine even augmented the TNF--induced GM-
CSF, IL-8 and IL-6 expression [111]. In addition, histamine
can augment through H1 receptor the interferon--induced
expression of MHC class I, ICAM-1, GM-CSF, CCL-5/
RANTES, CCL-2/MCP-1, CCL-20/MIP-3 and CXCL-10/
IP-10 in human keratinocytes [49].
In addition to the proinXammatory role of mast cells,
these cells can also be involved in the induction of toler-
ance or immunosuppression. For example, mast cells are
essentially involved in the induction of regulatory T cell-
dependent peripheral tolerance in a mouse model of skin
allografts, a reaction which appears to be related to the pro-
duction of IL-9, a mast cell growth and activation factor,
from activated regulatory T cells [106]. In a mouse model
of contact hypersensitivity using prolonged monitoring for
up to 15 days after challenge, mast cells have been shown,
unexpectedly, to be able to limit the inXammatory skin
reaction by producing the immunosuppressive cytokine IL-
10. In the same study, mast cells were also able to attenuate
the mouse skin reactions induced by multiple challenges
with ultraviolet irradiation for up to 30 days [54]. Further-
more, immunosuppression of mouse skin contact hypersen-
sitivity reaction by ultraviolet irradiation has been reported
to be dependent on CXCR4-positive mast cells which
migrate from the skin to the B cell area of draining lymph
node as a result of chemoattraction by CXCL-12 (stromal
cell-derived factor-1) [15]. In another mouse skin model,
mast cells and concomitant IL-10 expression in lymph
nodes have been reported to be critical intermediaries in the
mosquito bite-induced suppression of delayed-type hyper-
sensitivity reaction [30]. Hence, there are open questions
like in which immunological environment mast cells can123
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suppress it, and how these experimental results can be
linked to human skin diseases. Human mast cells have been
shown to express IL-10 [79] and therefore this cytokine is
one good candidate for mediating immunosuppressive
eVects of mast cells in some disease states. Interestingly,
IL-10 released from human mast cells can inhibit also mast
cell function in an autocrine or paracrine fashion [153].
In the psoriatic lesion, mast cells are increased in number
but at the same time also the percentage of mast cells show-
ing interferon- immunoreactivity is signiWcantly increased
in the upper dermis when compared with mast cells in the
non-lesional psoriatic skin [2] (Table 1), a result which
agrees with the well-known Wndings that psoriatic lesions
contain numerous Th1 type cells [190]. In addition, inter-
feron--positive mast cells in the psoriatic lesion correlate
with the psoriasis area and severity index score [2]. In con-
trast to psoriasis, mast cells in the atopic dermatitis lesions
show elevated amounts of IL-4 but are only weakly immu-
nopositive for interferon- [2, 69]. In addition, IL-4-positive
mast cells are signiWcantly associated with the size of aller-
gic skin prick-test wheal reaction and serum total IgE levels
[156]. Even though human mast cells have been shown to
express IL-6 and TGF-1 [88, 99]; it is, however, not
known to what extent mast cells contain these Th17 priming
cytokines in the psoriatic skin. Our preliminary results sug-
gest that mast cells contain IL-6 immunoreactivity in the
developing psoriatic lesion induced by the tape-stripping
technique (Suttle et al., unpublished results) (Fig. 2).
TNF- has emerged to be one crucial cytokine in the
psoriatic inXammation as evidenced by the rapidly expand-
ing clinical use of potent biological drugs targeted towards
this cytokine. Interestingly, mast cells are the predominant
source of preformed TNF- in normal skin [194], and along
with increased mast cell numbers also TNF--positive mast
cells are increased in number in the lesional psoriatic skin
[1]. However, increased TNF--positive mast cells have
been counted in the basal cell carcinoma lesions as well
[32]. Even though TNF- and histamine alone or in combi-
nation can activate keratinocytes for the production of pro-
inXammatory factors [1, 111], TNF- and histamine have
also properties which imply a regulatory role in the growth
of the epidermis [33, 72]. TNF- can inhibit the growth of
keratinocytes and this eVect is enhanced by heparin [63]. In
addition, the combination of TNF- and histamine leads to
strongly increased growth inhibition and even cytolysis of
normal keratinocytes in vitro [33]. Whether psoriatic kerat-
inocytes are resistant to the growth-inhibitory eVect of
TNF-, heparin and histamine in diVerent combinations
needs to be studied. CD30 ligand is another member of the
TNF superfamily expressed functionally in mast cells
[121]. Activation of the receptor of CD30 ligand, CD30, on
T cells in vitro leads to interferon- secretion in Th1 cell
clones and IL-4 and IL-5 secretion in Th2 cell clones [8]. In
the psoriatic lesion, the percentage of mast cells showing
immunoreactivity of CD30 ligand is signiWcantly increased
together with increased numbers of CD30-positive cells in
the upper dermis. Furthermore, mast cells can be induced
by means of reverse signalling through CD30 ligand to
express chemokines such as IL-8, MIP-1 and MIP-1
[42]. Thus, during the interaction between CD30 ligand on
mast cells and CD30 receptor on T cells both cells are pre-
sumably activated in the psoriatic lesion. This is not a spe-
ciWc feature to psoriasis since increased amounts of CD30
ligand have been observed in mast cells in atopic dermatitis
as well as in basal cell carcinoma lesions [32, 42]. Based on
Fig. 2 Interleukin-6 is localized 
to mast cells in the developing 
psoriatic lesion. The develop-
ment of the psoriatic lesion, i.e. 
the Köbner-phenomenon, was 
induced by the tape-stripping 
technique (see [61]) and a se-
quence of skin biopsies was tak-
en. The skin cryosection from a 
7-day-old lesion was Wrst 
stained. a Enzyme-histochemi-
cally for mast cell tryptase (red 
cells). After photographing and 
dissolving the red azo dye away 
with Tween 20 the same section 
was stained; b immunohisto-
chemically using mouse mono-
clonal anti-IL-6 antibody. Note 
that almost all tryptase-positive 
mast cells show IL-6 immunore-
activity. Also endothelial cells 
and other cells in the papillary 
dermis display IL-6123
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bly interact with T cells in the psoriatic lesion with diVerent
mechanisms as illustrated in Fig. 3. Mast cells can secrete
soluble mediators and express co-stimulatory molecules
needed for T cell recruitment and activation. Also, mast
cells can act as antigen presenting cells since they can
express MHC class I and II molecules.
Conclusions
Once dismissed as “allergy cells” the current knowledge
now indicates that mast cells have an essential role in the
immunopathological mechanisms of chronic inXammatory
diseases. Mast cells can be activated by a range of diVerent
mechanisms and they can synthesize and release rapidly or
secrete slowly potent preformed and newly synthesized
mediators as well as express cell surface ligands and recep-
tors, molecules which can be proinXammatory or induce
immunosuppression. Mast cells can also recruit the cells of
the immune system, such as T cells, neutrophils and eosin-
ophils, to the site of developing skin lesion, and they are
able to aVect keratinocytes, endothelial cells and sensory
nerves. Mast cells can migrate to the draining lymph node
and thereby aVect distant immune cells, or they can stimu-
late the maturation of Langerhans cells and dendritic cells
and their migration to lymph nodes. These cellular interac-
tions are crucial for the development of skin inXammation,
such as in the psoriatic lesion, where mast cells are activated
early in the lesion development followed by the increase in
MCTC mast cell number and in morphological contacts
between sensory nerves and mast cells. In addition, mast
cells show critical plasticity in the expression of cytokines
and other TNF family ligands, a feature which strongly sug-
gests that mast cells are involved in the immunoregulation
in psoriasis. In the chronic psoriatic lesion, mast cells accu-
mulated in the upper dermis are in the state of activation and
they constantly produce proinXammatory mediators which
promote perpetuation of the lesion. Several potent drugs
used for the treatment of psoriasis can aVect also mast cell
activity and/or cell number, such as cyclosporin A, cortico-
steroids, retinoids and even new biological TNF- or LFA-1
(CD11a/CD18) blocking drugs. Further studies are needed
to clarify in more detail which mediators and cell surface
molecules are, in fact, expressed in mast cells in psoriasis
compared to other skin diseases and their relation to clinical
severity. An important question to be answered is when and
how mast cell functions as a proinXammatory cell and when
and how as an immunosuppressive cell. It is also possible
that mast cells attempt to maintain skin homeostasis by pre-
venting excessive inXammation and epidermal growth but
fail in this task. These aspects need to be analyzed also in
animal models of psoriasis.
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